Published in Obesity and Diabetes Week, January 3rd, 2005
Results from this phase 1 study suggest that CG53135 is well tolerated following intravenous administration and support the company's strategy to investigate in phase 2 the safety and efficacy of a single dose of CG53135 for the prevention of oral mucositis.
"Oral mucositis is a severe side effect experienced by patients undergoing bone marrow...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.